1 active not recruiting, 1 enrolling by invitation. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Enrolling by invitation 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow RAB001 medium dose: new trials by email Literature Review of RAB001 medium dose trials Research Report on RAB001 medium dose
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase Ib Trial of Injectable RAB001 for Knee Osteoarthritis RAB001 medium dose - Knee Osteoarthritis | Phase 1 | Enrolling by invitation | ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. | 60 | 2026-04-16 | 2026-06-17 |
| A Phase II Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage Osteonecrosis of the Femoral Head RAB001 high dose, RAB001 medium dose, RAB001 low dose - Osteonecrosis, Osteonecrosis of the Femoral Head | Phase 2 | Active not recruiting | ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. | 161 | 2024-12-24 | 2026-03-24 |
Legg-Calve-Perthes Disease (1) · Osteoarthritis, Knee (1) · Osteonecrosis (1)
ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. (2)
China (2)